Pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
BEFREE |
The dual antagonist to both endothelin-1 type A and B receptors, Macitentan, has been approved for clinical management of pulmonary arterial hypertension while little is known about the secondary effect of the drug on spine.
|
30911541 |
2019 |
Pulmonary arterial hypertension
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Magnolol ameliorates pneumonectomy and monocrotaline-induced pulmonary arterial hypertension in rats through inhibition of angiotensin II and endothelin-1 expression.
|
30466619 |
2018 |
Pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the last thirty years since the discovery of endothelin-1, the therapeutic strategy that has evolved in the clinic, mainly in the treatment of pulmonary arterial hypertension, is to block the action of the peptide either at the ET(A) subtype or both receptors using orally active small molecule antagonists.
|
29947527 |
2018 |
Pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pulmonary vascular remodeling in pulmonary arterial hypertension involves perturbations in the nitric oxide (NO) and endothelin-1 (ET-1) pathways.
|
30260284 |
2018 |
Pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unraveling endothelin-1 induced hypercontractility of human pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension.
|
29649319 |
2018 |
Pulmonary arterial hypertension
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Endothelin-1 G5665T polymorphism was associated with pulmonary dysfunction (pulmonary artery hypertension and acute chest syndrome) and severe vaso-occlusive crises (VOC).
|
28548215 |
2018 |
Pulmonary arterial hypertension
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bucindolol attenuates the vascular remodeling of pulmonary arteries by modulating the expression of the endothelin-1 A receptor in rats with pulmonary arterial hypertension.
|
29710468 |
2018 |
Pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of aerobic exercise training on metabolism of nitric oxide and endothelin-1 in lung parenchyma of rats with pulmonary arterial hypertension.
|
28181133 |
2017 |
Pulmonary arterial hypertension
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In PAECs isolated from patients with pulmonary arterial hypertension, microRNA (miR)-98 expression was reduced, and ET-1 protein levels and proliferation were increased.
|
26098770 |
2016 |
Pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.
|
26252367 |
2015 |
Pulmonary arterial hypertension
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, important molecular pathways that are central to the pathogenesis of pulmonary arterial hypertension are reviewed, including nitric oxide, prostacyclin, endothelin-1, reactive oxygen species, and endothelial and smooth muscle proliferation.
|
24951762 |
2014 |
Pulmonary arterial hypertension
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Viral Toll Like Receptor activation of pulmonary vascular smooth muscle cells results in endothelin-1 generation; relevance to pathogenesis of pulmonary arterial hypertension.
|
22960172 |
2012 |
Pulmonary arterial hypertension
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension.
|
21773759 |
2012 |
Pulmonary arterial hypertension
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension.
|
20562228 |
2010 |